Multicenter prospective randomized open with a blinded end point (PROBE) parallel-group study on treatment with biphasic insulin BIAsp70/30 and short-acting insulin or rapid-acting analogue plus glargine in comparison with short-acting insulin or rapidacting analogue plus glargine to evaluate the metabolic control and quality of life (QoL) in children and adolescents with type 1 diabetes mellitus over 12 months

Trial Profile

Multicenter prospective randomized open with a blinded end point (PROBE) parallel-group study on treatment with biphasic insulin BIAsp70/30 and short-acting insulin or rapid-acting analogue plus glargine in comparison with short-acting insulin or rapidacting analogue plus glargine to evaluate the metabolic control and quality of life (QoL) in children and adolescents with type 1 diabetes mellitus over 12 months

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2012

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top